Table 1.
Treatments and survival characteristics of VRL patients
| Patient | BTKi treatment (months) | Initial response (1 month) | Complications | Ocular relapse after initial remission (months) | CNS progression | PFS# (months) | OS* (months) | Survival status | Follow-up ꝉ (months) |
|---|---|---|---|---|---|---|---|---|---|
| #1 |
Z (6) O (3) |
CR | No | Bilateral eyes (9.1) | No | 9.1 | 21 + | Alive | 21 |
| #2 | Z (4) | CR | Ecchymosis (grade 1) | Bilateral eyes (7.5) |
10 months after BTKi discontinuation |
7.5 | 20 + | Alive | 20 |
| #3 | O (18) | CR | Ecchymosis (grade 1) | No | No | 18 + | 18 + | Alive | 18 |
| #4 | Z (1) | PD | No | No | 1.2 months since BTKi treatment | 1.2 | 2 | Dead due to CNS progression | 2 |
| #5 |
O (6) Z (6) |
PR |
Arthralgia (grade2) Ecchymosis (grade 1) |
No | 11.6 months since BTKi treatment | 11.6 | 12 + | Alive | 12 |
| #6 | O (9) | CR | No | No | No | 9 + | 9 + | Alive | 9 |
| #7 | O (7) | CR | No | No | No | 7 + | 7 + | Alive | 7 |
| #8 | I (6) | CR | No | No | No | 6 + | 6 + | Alive | 6 |
| #9 | O (3) | PR | No | No | No | 3 + | 3 + | Alive | 3 |
| #10 | O (3) | CR | No | No | No | 3 + | 3 + | Alive | 3 |
BTKi, Bruton tyrosine kinase inhibitors; CNS, central nervous system; CR, complete remission; PD, progressive disease; PFS, progression-free survival; PR, partial remission; I, ibrutinib; O, orelabrutinib; OS, overall survival; Z, zanubrutinib
# PFS was calculated as the period from the onset of BTK inhibitors to lymphoma relapse, death, or the final follow-up
*OS was computed from the date of BTKi initiation to the date of the last follow-up or death
ꝉ Follow-up was calculated from the onset of BTK inhibitors until death or the last follow-up